Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers ...
Biogen is a significant player in the $20 billion global MS market with Avonex, Plegridy, Tysabri, and Tecfidera. The launch of Vumerity partly protects Tecfidera sales from generic headwinds in ...
1 Pegylated IFN β-1a (PLEGRIDY®, Biogen) was US Food and Drug Administration (FDA)– and European Medicines Agency (EMA)–approved in 2014. Establishing new more holistic methods to evaluate ...
Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers ...
Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers ...
Biogen, Inc. is a biopharmaceutical company ... Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM ...
Biogen's Q4 2024 earnings showed slight revenue ... The patent expiries of Tecfidera, Plegridy, and Tysabri have been chiefly responsible for the declines, and although Vumerity, approved in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback